Sotillo et al., 2015 - Google Patents

Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy

Sotillo et al., 2015

View HTML
Document ID
3226437564403673548
Author
Sotillo E
Barrett D
Black K
Bagashev A
Oldridge D
Wu G
Sussman R
Lanauze C
Ruella M
Gazzara M
Martinez N
Harrington C
Chung E
Perazzelli J
Hofmann T
Maude S
Raman P
Barrera A
Gill S
Lacey S
Melenhorst J
Allman D
Jacoby E
Fry T
Mackall C
Barash Y
Lynch K
Maris J
Grupp S
Thomas-Tikhonenko A
Publication year
Publication venue
Cancer discovery

External Links

Snippet

The CD19 antigen, expressed on most B-cell acute lymphoblastic leukemias (B-ALL), can be targeted with chimeric antigen receptor–armed T cells (CART-19), but relapses with epitope loss occur in 10% to 20% of pediatric responders. We detected hemizygous …
Continue reading at aacrjournals.org (HTML) (other versions)

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Hybridisation probes
    • C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Hybridisation probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Similar Documents

Publication Publication Date Title
Sotillo et al. Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy
Barkal et al. Engagement of MHC class I by the inhibitory receptor LILRB1 suppresses macrophages and is a target of cancer immunotherapy
Gu et al. Silencing of LINE-1 retrotransposons is a selective dependency of myeloid leukemia
Hunter et al. The genomic landscape of Waldenström macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis
Yildiz et al. Activating STAT6 mutations in follicular lymphoma
Damm et al. Acquired initiating mutations in early hematopoietic cells of CLL patients
Steidl et al. MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers
Parry et al. Genetics and prognostication in splenic marginal zone lymphoma: revelations from deep sequencing
Mansouri et al. Functional loss of IκBε leads to NF-κB deregulation in aggressive chronic lymphocytic leukemia
Gunawardana et al. Recurrent somatic mutations of PTPN1 in primary mediastinal B cell lymphoma and Hodgkin lymphoma
Huang et al. Cooperative transcriptional repression by BCL6 and BACH2 in germinal center B-cell differentiation
Hu et al. A genome-wide regulatory network identifies key transcription factors for memory CD8+ T-cell development
Solomon et al. Cohesin gene mutations in tumorigenesis: from discovery to clinical significance
Kashima et al. Single-cell analyses reveal diverse mechanisms of resistance to EGFR tyrosine kinase inhibitors in lung cancer
Cao et al. An unexpected role for p53 in regulating cancer cell–intrinsic PD-1 by acetylation
Rakowski et al. Convergence of the ZMIZ1 and NOTCH1 pathways at C-MYC in acute T lymphoblastic leukemias
Proctor et al. Identification of PD-L2, B7-H3 and CTLA-4 immune checkpoint proteins in genetic subtypes of meningioma
Doménech et al. New mutations in chronic lymphocytic leukemia identified by target enrichment and deep sequencing
Pyrzynska et al. FOXO1 promotes resistance of non-Hodgkin lymphomas to anti-CD20-based therapy
Aksenova et al. Genome instability in multiple myeloma: Facts and factors
Roos-Weil et al. A recurrent activating missense mutation in Waldenström macroglobulinemia affects the DNA binding of the ETS transcription factor SPI1 and enhances proliferation
Schlager et al. Inducible knock-out of BCL6 in lymphoma cells results in tumor stasis
Matsuo et al. Recurrent CCND3 mutations in MLL-rearranged acute myeloid leukemia
Pandzic et al. Transposon mutagenesis reveals fludarabine resistance mechanisms in chronic lymphocytic leukemia
Zhou et al. Super-enhancer-driven TOX2 mediates oncogenesis in Natural Killer/T Cell Lymphoma